Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
Breast cancer is still the leading cause of death in patients with malignant tumors. Among women with breast cancer, standard combination chemotherapy with anthracyclines and taxanes reduces mortality from this disease by about one third compared to patients not receiving chemotherapy and is the sta...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5f4e68188d1b418fb57bc9b19ae96a98 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5f4e68188d1b418fb57bc9b19ae96a98 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5f4e68188d1b418fb57bc9b19ae96a982021-11-30T17:03:34ZImproving early breast cancer treatment: the role of granulocyte colony-stimulating factor1815-14341815-144210.26442/18151434.2020.4.200510https://doaj.org/article/5f4e68188d1b418fb57bc9b19ae96a982021-02-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/61161/44250https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Breast cancer is still the leading cause of death in patients with malignant tumors. Among women with breast cancer, standard combination chemotherapy with anthracyclines and taxanes reduces mortality from this disease by about one third compared to patients not receiving chemotherapy and is the standard for neoadjuvant or adjuvant chemotherapy of breast cancer. Understanding the patterns of tumor growth has made it possible to improve the current paradigms of the treatment of early forms of breast cancer and to use dose-dense chemotherapy regimens to achieve better treatment results. Nowadays, chemotherapy in a dose-dense regimen for breast cancer is the preferred option in all world and Russian clinical guidelines. However, the use of such chemotherapy regimens significantly increases the incidence of side effects, primarily febrile neutropenia. The appearance of more effective methods of supportive care, particularly short-acting and long-acting granulocyte colony-stimulating factor, in clinical practice has made it possible to use dose-dense chemotherapy regimens to increase the effectiveness of the treatment.Inna P. GanshinaKristina A. IvanovaElena V. LubennikovaAlexandr V. ArkhipovLiudmila G. ZhukovaIP Habib O.N.articlebreast cancerdose-dense chemotherapy regimensgranulocyte colony-stimulating factorempegfilgrastimNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 4, Pp 86-90 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
breast cancer dose-dense chemotherapy regimens granulocyte colony-stimulating factor empegfilgrastim Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
breast cancer dose-dense chemotherapy regimens granulocyte colony-stimulating factor empegfilgrastim Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Inna P. Ganshina Kristina A. Ivanova Elena V. Lubennikova Alexandr V. Arkhipov Liudmila G. Zhukova Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor |
| description |
Breast cancer is still the leading cause of death in patients with malignant tumors. Among women with breast cancer, standard combination chemotherapy with anthracyclines and taxanes reduces mortality from this disease by about one third compared to patients not receiving chemotherapy and is the standard for neoadjuvant or adjuvant chemotherapy of breast cancer. Understanding the patterns of tumor growth has made it possible to improve the current paradigms of the treatment of early forms of breast cancer and to use dose-dense chemotherapy regimens to achieve better treatment results. Nowadays, chemotherapy in a dose-dense regimen for breast cancer is the preferred option in all world and Russian clinical guidelines. However, the use of such chemotherapy regimens significantly increases the incidence of side effects, primarily febrile neutropenia. The appearance of more effective methods of supportive care, particularly short-acting and long-acting granulocyte colony-stimulating factor, in clinical practice has made it possible to use dose-dense chemotherapy regimens to increase the effectiveness of the treatment. |
| format |
article |
| author |
Inna P. Ganshina Kristina A. Ivanova Elena V. Lubennikova Alexandr V. Arkhipov Liudmila G. Zhukova |
| author_facet |
Inna P. Ganshina Kristina A. Ivanova Elena V. Lubennikova Alexandr V. Arkhipov Liudmila G. Zhukova |
| author_sort |
Inna P. Ganshina |
| title |
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor |
| title_short |
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor |
| title_full |
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor |
| title_fullStr |
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor |
| title_full_unstemmed |
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor |
| title_sort |
improving early breast cancer treatment: the role of granulocyte colony-stimulating factor |
| publisher |
IP Habib O.N. |
| publishDate |
2021 |
| url |
https://doaj.org/article/5f4e68188d1b418fb57bc9b19ae96a98 |
| work_keys_str_mv |
AT innapganshina improvingearlybreastcancertreatmenttheroleofgranulocytecolonystimulatingfactor AT kristinaaivanova improvingearlybreastcancertreatmenttheroleofgranulocytecolonystimulatingfactor AT elenavlubennikova improvingearlybreastcancertreatmenttheroleofgranulocytecolonystimulatingfactor AT alexandrvarkhipov improvingearlybreastcancertreatmenttheroleofgranulocytecolonystimulatingfactor AT liudmilagzhukova improvingearlybreastcancertreatmenttheroleofgranulocytecolonystimulatingfactor |
| _version_ |
1718406382244331520 |